Keen Vision Acquisition Corp.
Company Information
Industry
Blank Checks
SIC Code
6770
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
Business Address
37 GREENBRIAR DRIVE, SUMMIT, NJ, 07901
Mailing Address
37 GREENBRIAR DRIVE, SUMMIT, NJ, 07901
Phone
(203) 609-1394
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$7.41M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 25, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 6, 2026 | View on SEC |
| 8-K Current report of material events | January 26, 2026 | View on SEC |
| 8-K Current report of material events | January 5, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | January 5, 2026 | View on SEC |
| 8-K Current report of material events | November 24, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 10, 2025 | View on SEC |
Annual Reports
10-K
March 25, 2026
- Keen Vision announced a new merger agreement with biotech firm Novoheart Group Limited (NVH).
- The deal shifts the company's focus toward high-tech medical research using 'MyoChip' heart tissue simulation.
Related Companies
Companies in the same industry (SIC: 6770)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.